Arthur Mabaquiao, MD
Rheumatology · San Diego, CANPI 1730271933
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $128,824 of the $208,576 with a category attached, or 61.8%. 60 manufacturers reported payments, led by Amgen at 50.2% of the total. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,248 payments — averaging $92.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$105K
- UCB, Inc.$46K
- Mallinckrodt Enterprises LLC$13K
- Actelion Pharmaceuticals US, Inc.$9K
- Mallinckrodt Hospital Products Inc.$6K
- AstraZeneca$4K
- plus $26K from 54 others
Across 345 payments — averaging $4027.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$410K
- Amgen$190K
- Regeneron$100K
- Mesoblast, Inc.$100K
- E.r. Squibb & Sons, L.L.C.$82K
- Astrazeneca UK Limited$79K
- plus $429K from 14 others
What the payments were for
- Consulting fees$16,0258%
- Speaking & faculty fees$128,82462%
- Travel & lodging$13,8767%
- Food & beverage$49,38924%
- Education$4630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$208,576 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 58 | $3,002,153 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $468,129 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $376,134 |
| Xeljanz XrTofacitinib Citrate | 52 | $309,504 |
| Humira(Cf) PenAdalimumab | 37 | $249,194 |
| Enbrel SureclickEtanercept | 33 | $246,150 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 21 | $227,914 |
| Cimzia (2 Pack)Certolizumab Pegol | 25 | $196,666 |
| Taltz AutoinjectorIxekizumab | 28 | $189,689 |
| RinvoqUpadacitinib | 27 | $160,719 |
| Enbrel MiniEtanercept | 21 | $152,432 |
| RemicadeInfliximab | 13 | $119,536 |
| KevzaraSarilumab | 23 | $98,242 |
| Orencia ClickjectAbatacept | 17 | $96,599 |
| SimponiGolimumab | 16 | $96,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $5,562 | $3,002,15358 claims |
| CSL BehringHizentra, Privigen | $240 | $844,26325 claims |
| PfizerOctagam, Xeljanz | $1,880 | $283,76034 claims |
| Johnson & JohnsonRemicade, Simponi | $2,692 | $215,78729 claims |
| AmgenEnbrel, Otezla, Prolia | $104,692 | $205,38851 claims |
| UCB, Inc.Cimzia (2 Pack) | $45,831 | $196,66625 claims |
| AbbVieRinvoq, Savella | $3,851 | $174,70744 claims |
| SanofiKevzara | $484 | $98,24223 claims |
| Novo NordiskRybelsus | $123 | $18,15717 claims |
| Hikma Pharmaceuticals USABuprenorphine | $18 | $5,14021 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $165 | $3,76979 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in San Diego
- Ara DikranianSan Diego$2.2M
- Kenneth KalunianSan Diego$194K
- Sudhakar TumuluriSan Francisco$2.8M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.